Dr. Antonio Rossi stands as a prominent leader in oncology clinical research and therapeutic development with extensive expertise in thoracic malignancies. He currently serves as Senior Medical Director within the Oncology Hematology Center of Excellence at IQVIA, providing strategic scientific leadership for global clinical development programs in cancer therapeutics. Based at IQVIA's Milan office, Dr. Rossi has cultivated a distinguished career that bridges clinical medicine with pharmaceutical innovation and evidence generation. His specialized focus on non-small cell lung cancer has positioned him at the forefront of evolving treatment paradigms in this challenging disease space. With deep clinical experience and strategic vision, Dr. Rossi plays a critical role in advancing novel therapeutic approaches from development through real-world application.
Dr. Rossi has made seminal contributions to understanding immunotherapy integration in early-stage non-small cell lung cancer, co-authoring influential analyses on the transformative impact of immune checkpoint inhibitors in the neoadjuvant setting. His research examining the critical relationship between time-to-surgery intervals following chemoimmunotherapy and pathological response rates has provided essential evidence for optimizing treatment sequencing in lung cancer patients. His work has established important correlations between surgical timing windows and achievement of major pathological response, directly informing clinical practice guidelines. Through high-impact publications in respected medical journals, Dr. Rossi has helped shape the evolving standard of care for resectable lung cancers in the immunotherapy era.
Beyond his research contributions, Dr. Rossi serves as Editor-in-Chief for EMJ Respiratory, where he guides the dissemination of cutting-edge clinical evidence and therapeutic advances in respiratory medicine. His leadership at IQVIA positions him at the epicenter of global oncology clinical trial innovation, particularly in the complex domain of combination therapies and biomarker-driven treatment strategies. Dr. Rossi actively contributes to advancing trial readiness initiatives worldwide, as demonstrated by his participation in IQVIA's India in Focus Lung Cancer Trial Readiness event. His ongoing work continues to address pivotal questions regarding optimal treatment sequencing, pathological response metrics, and long-term survival outcomes, ensuring that scientific advances translate into meaningful improvements in patient care across diverse healthcare settings.
